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Chapter VIII 
The Present Status of Colchicine and Uricosuric 
Agents in Management of Primary Gout 
By WILLIAM D. ROBINSON, M. D. 
Unizjersity of Michigan Medical School 
It is conventional to divide the management of gout into the treatment 
of the acute attacks, the interim treatment, and treatment of the tophaceouy 
stage.' It is probably fair to say that, at least until 1950, virtually every- 
thing we did in the management of patients with gout was empiric. The 
use of colchicine developed on a purely empiric basis and has a respectable 
and fascinating history; the only significant clues to possible mode of ac- 
tion of colchicine have developed within the last few years and have been 
thoroughly discussed. When colchicine is given by mouth, there is quite 
general agreement on the dosage with 0.5 mg. or 0.6 mg. tablets, usually 
given one every hour, until pain is clearly relieved, or until evidence of toxicity 
develops, or until a total dose somewhere in the range of 71/2 to 10 mg. of 
the drug has been given. By intravenouy administration, the total amount of 
colchicine is usually limited to about 3 mg., given in divided doses. I was 
quite interested in Dr. Seegmiller's use of an intravenous dose as high as 5 mg. 
in 24 hours in some of the studies which he reported. He tells me that there 
were no serious side effects from a dose of this magnitude. 
The pattern and specificity of response to colchicine has come up for dis- 
cussion. As Drs. Zuckner and Wallace have pointed out, the interpretation 
of the therapeutic trial with colchicine depends a great deal on what is ex- 
pected of it. Most of us would agree that in the classic severe podagra, when 
there is a fiery red, swollen joint, with overlying skin at maximum tension, 
there is relatively little difficulty in evaluating the response to colchicine. 
With the administration of colchicine there is a subjective dicrease in the 
excruciating pain several hours before there is any convincing objective 
change. The first objective change occurs between six and twelve hours 
after the last dose of colchicine. This is a diminution in swelling, seen as the 
skin becomes a little bit wrinkled and loses the taut, shiny appearance. 
Within 24 hours there usually is some reduction in redness and swelling but 
a considerable redness may remain. Complete subsidence may not be seen 
for 48 to 72 hours. 
The real difficulty in evaluating this therapeutic trial is in more chronic 
situations, where redness and marked swelling are not as apparent. Under 
these circumstances, colchicine does not produce as dramatic results and 
the ability to distinguish the response to colchicine in this situation from 
the effect which may occur in other types of joint disease may present 
real difficulty. 
The well established attack and the polycyclic attack frequently respond 
incompletely to colchicine. Figures on the percentage of acute attacks which 
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will be controlled by colchicine used in the conventional manner will de- 
pend a great deal on the stage and relative intensity of the joint inflam- 
mation; the more acute the degree of inflammation, the more impressive is 
the response to colchicine. 
The next point with respect to colchicine is its use in preventing relapses 
after acute attacks and its usefulness in reducing the frequency of acute 
attacks in interim management. It has become quite well accepted that 
maintenance colchicine in doses of 2 to 3 tablets a day should be used for 
a few weeks after the treatment of acute attacks of gout. It is usually recom- 
mended for at least a three week period and it is indispensable if the second- 
ary attacks or withdrawal attacks after the use of corticosteroids or ACTH 
are to be prevented. 
The interim management of gout has two objectives. One is the use of 
measures that reduce the frequency of recurrent attacks and the second 
objective is to induce negative urate balance. 
I know that there still is some difference of opinion with respect to the 
value of colchicine in preventing or reducing the incidence of attacks of 
gout. Most patients will tolerate three colchicine tablets a day without diar- 
rhea; there are a few that can take up to four, there are a few that cannot 
tolerate more than one. The customary dose is one tablet twice a day as 
interim management. 
The evidence for the effectiveness of colchicine in reducing the frequency 
of recurrent attacks stems from two types of observations. In many studies 
using the patient as his own control, the frequency of attacks prior to the 
institution of maintenance therapy is estimated, and a subsequent reduction 
in the frequency of attacks is reported. This of course is subject to very real 
criticisms and I know of no way in which such a study has been done in 
a double blind fashion. A second and somewhat more impressive line of 
evidence is the ability of colchicine to reduce the frequency of acute at- 
tacks in patients who are subjected to specific precipitating factors which 
frequently will produce acute gout attacks. Examples are the ability of 
colchicine to reduce, almost to the point of elimination, postoperative at- 
tacks of gout, and its ability to reduce the frequency of acute attacks in 
patients fasting or on a high fat diet. I personally was very much impressed 
with the ability of colchicine to prevent the acute attacks of gout associated 
with withdrawal of ACTH administration. 
Until 1951 most efforts to induce negative urate balance concentrated on 
attempts to decrease dietary intake of purines and the use of salicylates, 
usually in an intermittent fashion because they were not tolerated by continu- 
ous administration as uricosuric agents. With the advent of more effecti\~e 
uricosuric agents it has been possible to reduce the serum uric acid much 
more effectively than had been possible before. 
For the purposes of this conference, there would seem to be little merit 
in discussing in detail the similarities and differences of each uricosuric 
agent. I t  would seem more profitable to review the experience with a group 
of patients who have been followed for a considerable period of time on 
combined management with colchicine and uricosuric agents, with the ob- 
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jectives of seeing to what extent our concepts can be modified or influenced 
by developments during the past year or two and in the light of the discus- 
sions at this conference. The point of departure is previously-reported ob- 
servations on a group of 64 patients with primary gout, observed over a pe- 
riod of years in the Rackham Arthritis Research Unit at The University of 
Michigan Medical Center.2 Our experience has been quite similar to that 
reported by others. 
In this group of 64 patients there were 60 males and 4 females. The 
average age at the onset of clinical gout was 36.7 years. 
The initial attack occurred before the age of 20 years in 8 cases, between 
the ages of 20 and 40 years in 30, and after the age of 40 in 26 patients (Table 
32).  The average age at the time uricosuric therapy was initiated was 49.7 
years. Duration of total follow-up and duration of uricosuric therapy are 
shown in Table 33. 
Eleven patients received uricosuric drugs for 5 years or more, 22 were fol- 
lowed for at least 3 years after uricosuric drugs were instituted, and 40 
patients were observed for at least 18 months on these drugs. In view of the 
discussions at this conference, it is of interest to note that five of these pa- 
tients had diabetes mellitus and that an additional patient was one of the 
seven patients with the type of glycogen storage disease previously dis- 
cussed. Thirty of this group could be classified as hypertensive, with 
blood pressure levels in excess of 150/100. In 43 of the 64 patients, the ratio 
of urate clearance to creatinine clearance was determined prior to the 
administration of uricosuric drugs. At least five of these 38 patients could 
be classified as hyperexcretors, with the urate clearance ratio exceeding 
10 per cent. Eight of these patients died during the period of observation, 
seven of them from cardiovascular renal disease, one from pneumonia. 
At  the time of initiation of uricosuric therapy, 50 of these 64 patients had 
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definite tophi; the other patients either had chronic gouty arthritis, a serum 
uric acid above 8 mg. per cent, or both. 
The uricosuric agents used in this study are listed in Table 34. AS several 
patients received more than one drug during a period of follow-up, a total 
of 94 experiences with the various drugs was obtained in the 64 pa- 
tients. In general, the drug dosage was adjusted for each individual pa- 
tient with the overall objective of reaching a serum uric acid of 6 mg. 
per cent or lower. It is evident that the most extensive experience was with 
probenecid. 
As an overall appraisal, the results of colchicine and uricosuric therapy 
may be classified as good, moderate, and poor. In this series, the results 
are classified as good in 23 individuals, about one third of the total group. 
These patients experienced a marked reduction and frequency of acute at- 
tacks, maintenance of the serum uric acid at 6 mg. per cent or lower, and a 
decrease in size of tophi if they were originally present. In 13 of these pa- 
tients, approximately 20 per cent, the results were classified as poor. In gen- 
eral these were uncooperative patients. Although they came under control 
fairly well while in the hospital, they failed to return for follow-up visits and 
were seen a year to several years later with severe gout and increase in size 
of tophi. 
Of particular interest is a group of 28 of these 64 patients in whom the 
results could be classified as moderately satisfactory although good control 
was never established. While the frequency of attacks of acute gout was 
decreased, such attacks were not eliminated; tophi did not decrease in size, 
although they did not progress; serum uric levels were usually lowered but 
were not impressively reversed toward normal. In 22 of the 28 patients in 
this group the difficulty could be related to lack of cooperation on the part 
of the patient; the patients were frequently satisfied, but the physician was 
not satisfied with the degree of control of hyperuricemia which had been 
attained. More important, however, are the six patients in this group with 
significant renal disease. In these patients, the ability to reduce the serum 
uric acid in the face of serious impairment of renal function presented a 
problem, in spite of the diligent application of various drug regimens in 
fully cooperative patients. 
The serum urate levels before and during uricosuric therapy are presented 
in Table 35. The average serum uric concentration before treatment exceeded 
8 mg. per cent in 50 patients. During the course of therapy the average serum 
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Table 3S.-Serurn Urate Response to Uricosuric Therapy 
No. of Patients 
Average Serum Urate Before therapy On therapy 
10.1 mg. % or greater 18 4 
8.1-10.0 ing. % 32 9 
7.1-8.0 mg. % 11 4 
6.1-7.0 mg. % 2 14 
6.0 or less 1 31 
Total 64 62 
Table SSa.-Effect of Uricosuric Drugs and Colchicine on Attacks of Acute Gout 
No. of Patients 
After therapy -4ttacks Der Year nefore the raw 
1 or less per year 3 35 
2-5 23 14 
6-10 16 1 
11 or more 8 0 
Total 50 50 
uric acid was reduced to 6 mg. per cent or less in 31 patients, and below 8 mg. 
per cent in 49 patients. 
The effect of the combination of colchicine and uricosuric drugs on the 
frequency of acute attacks of gout in 50 patients is presented in Table 35a. 
The data indicate a very distinct decrease in frequency of acute attacks, 
35 patients having an average of one or less attacks per year. 
In 20 patients it was possible to evaluate the effects of colchicine alone 
on the frequency of acute gout, prior to the administration of uricosuric 
agents. In 15 of these 20 there was a definite decrease in frequency of acute 
attacks, and in 11 there was reduction to less than one attack per year. How- 
ever in five there was no marked improvement. In three patients there had 
been a decrc,asc in frequency of attacks on colchicine alone, but with ade- 
quate iiricosuric therapy there was an additional decrease to one attack or 
less per year. Other patients, in whom recurrence of acute gouty arthritis 
was well controlled on a regimen of both maintenance colchicine and uri- 
cosmic drugs, on stopping colchicine experienced a recurrence of attacks. 
One patient, a physician, was able to stop colchicine without difficulty after 
several years on successful combined therapy. 
Of interest is a comparison (Table 36) of a group of patients in whom tophi 
decreased in size as compared to those patients in whom tophi did not 
appear to change. 
The average serum uric acid before treatment in the 17 patients in whom 
the tophi decreased in size before treatment did not appear to differ 
significantly from the average serum uric acid before treatment in the 33 
patients in whom the tophi appeared unchanged. However the average serum 
uric acid during treatment was distinctly lower in those in whom the tophi 
became smaller. During this conference we have had several lines of evi- 
dence suggesting that hyperuricemia becomes clinically significant at a level 
870 GOUT AND PURINE METABOLISM 
Table 36.-Comparison of Response to 50 Patients with Tophi 
Tophi smaller Tophi unchanged 
No. of patients 17 33 
Average serum urate 9.05 mg. % 9.76 mg. X 
(range-7.1 to 11.4 mg.%) (range-6.5 to 22.3 mg.%) 
Average serum nrate 5.77 mg. % 7.07 mg. % 
( range4.6 to 11.2 mg. % )  
s = 1.82 
on treatment (range-3.6 to 7.9 mg. W )  
s z 1.12 
Average baseline urate 5.8% 6.8% 
cxcretion-measured (range-3.1 to 8.7%) (range-2.5 to 12.0%) 
by U.C./Cr.C. 
Average baseline mate 13.3% 13.7% 
Cooperation on 24-holir 88% 70% 
on therapy U.C./Cr.C. (range-3.2 to 31.7%) (range-6.4 to 29.3%) 
urine collections ( 15 of 17 patients ) (23  of 33 patients) 
% patients followed 
over 1% years 59% 27% 
of about 7 mg. per cent; and it may be significant that the average serum 
uric acid was not reduced below this level in the group of patients in whom 
the tophi were unchanged. There appears to be no significant difference be- 
tween the two groups with respect to the average uric acid excretion either 
before or during therapy. The cooperation of the patient, at least as re- 
flected in their collection of 24-hour urine specimens, appears to be some- 
what better in the group in whom the tophi became smaller. Perhaps of great- 
est significance is the fact that the period of observation on the average 
was considerably longer in patients in whom the tophi became smaller. This 
suggests that the conclusions as related to time should be reserved for more 
prolonged observations. 
In Table 37 is presented a summary of the results of combined treatment. 
In 70 per cent of the patients the acute gouty attacks were reduced to one 
attack per year or less. In one-half of the patients the serum uric was reduced 
to below 6 mg. per cent. In one-third of the patients with tophi there was 
a decrease in size of tophi. In 23 per cent of this group there appeared to 
be precipitation of acute gouty arthritis by the initiation of uricosuric treat- 
ment. I appreciate that our experience with respect to this phenomenon has 
given a somewhat greater incidence than that observed by others. This may be 
due to the fact that this series does include a group of patients who were 
started early in the use of uricosuric agents, in whom maintenance colchicine 
was not in effect at the time the uricosuric agents were started. However, 
the occurrence of acute gouty arthritis a few days to a couple of weeks after 
the administration of uricosuric agents has been impressive in our experience, 
and in some individuals has not been prevented by maintenance colchicine. 
Of particular interest is the occurrence of renal calculi during uricosuric 
therapy in 7 of the 64 patients (11 per cent). However, in this group there 
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Table 37.-Summaru of Results of Treatment in 64 Cases of Primarq Gout 
yG Patients 
Iniprovcment in chronic gout 
Dccrease in acute gouty arthritiq to 1 attack per year 
Ilecrease in serum urate to normal 
Decrease in size of tophi 
Precipitation of acute gouty arthritis by drugs 
Died during follow-up period 















are five patients who had experienced renal calculi before they were given 
iiricosiiric agents. No conclusions with respect to the incidence of renal cal- 
culi on uricosuric therapy appeared justified on the basis of this experience. 
In the light of discussion at this conference, particular interest centers on 
the matter of renal function in patients with gout, and the effect of uricosuric 
therqiy on renal function. Dr. Gutman has presented to us in beautiful and 
logicd detail the concept that the handling of urates by the kidney is de- 
signed to protect the collecting system in the kidney from being clogged up 
by uric acid crystals. If this concept is correct, in the use of uricosuric agents 
we are interfering with a protective mechanism. Therefore, I am most in- 
terested in determining whether clinical improvement in renal function has 
been observed in patient.; receiving uricosuric agents over a period of time. 
In this group of patients, pre-treatment data were available in 44 patients 
in terms of serum creatinine levels and the 24 hour endogenous creatinine 
clearance. On the basis of these data renal function remained unchanged 
in 35 (80 per cent), deteriorated in 8 (18 per cent), and possibly improved 
in one ( 2  per cent). 
There is one situation which has to be kept in mind in interpreting 
changes of renal function in gouty patients. We have all seen patients 
who have come in the hospital with acute attacks of gout, usually with con- 
siderable fever, who in addition to a sharp increase in their serum urate 
levels have had elevation of blood urea nitrogen and of serum creatinine. 
In some of these we can find evidence of infection and appreciate that there 
is coincident pyelonephritis along with the acute attack of gout. In others, 
one can conclude by inference that there must be some blockade in the col- 
lecting system, although a definite obstruction cannot be demonstrated. With 
appropriate management, emphasizing the use of antibiotics and hydration, 
rapid improvement in renal function may be obtained, with the return to a 
normal blood urea nitrogen and an improved level of serum creatinine, al- 
though usually some residual impairment of creatinine clearance can he 
demonstrated. The one patient in this series who was classified as possibly 
improved with respect to renal function happened to have uricosuric agents 
administered during the management of such an episode. It would obviously 
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be in error to attribute the improvement in renal function under these cir- 
cumstances to the uricosuric agents. 
I personally am not convinced that I have seen or heard reported clear- 
cut evidence of real improvement of renal function in patients on uricosuric 
therapy. This perhaps can be regarded as one of the real shortcomings of 
attempting to induce negative urate balance by increasing urinary urate ex- 
cretion. This leads to the hope that the prospects for preventing the renal 
complications of gout may be better with the use of agents which induce 
negative urate balance by decreasing the production of uric acid. 
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Discussion 
DR. BARTELS: Butazolidine is so effective in the treatment of acute at- 
tacks that I think it should be discussed. I consider that Butazolidine is more 
effective and a better drug than colchicine. I realize that colchicine given 
intravenously is effective but it is inapplicable as home treatment and few 
patients with acute gouty arthritis require hospital care. Colchicine when 
given in a dose of 5/10 of a milligram hourly for six or eight doses almost 
uniformly produces objectionable side effects. Butazolidine, on the other 
hand, produces no side effects and can be good home treatment. We have 
a high surgical population in our hospital and the use of colchicine in our 
surgical patients, either preoperatively or postoperatively, is certainly objec- 
tionable whereas Butazolidine is effective. 
We have now treated 134 patients with Butazolidine for acute attacks. 
Given in a dose of 800 mg. daily for one or two days, it is as effective 
as colchicine. There have been no immediate side effects and we have not 
seen any side effects from its use every three or four weeks or even every 
one or two months. Therefore this drug, it seems to me, should take the 
place of colchicine in clinical practice. 
DR. C. SMYTH: I share your personal feelings about this drug. From the 
practical standpoint, phenylbutazone is just as effective as colchicine. 
DR. LOCKIE: Frankly, I am a Butazolidine man after the diagnosis of gouty 
arthritis has been established, using colchicine in the treatment of the first 
attack which I see. We have not had any side effects in the dosage of 800 
mg. of Butazolidine for one or two days in a large series of treatments 
of acute attacks. 
I’d like to mention a unique experience with colchicine. The other day I 
saw a 37 year old lady, referred by a psychiatrist who had treated her for 
degenerative arthritis of the hands, who had been using colchicine, 500 mi- 
crograms twice daily or three times daily, which had been given to her in 
a prescription nine years previously, along with phenobarbital. Well, she 
didn’t want to take two drugs a day, and she decided to take colchicine, 
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which she thought was the nerve tonic, and for nine years she had taken 500 
micrograms, 3 times a day, during which time she has had three normal 
pregnancies. 
DR. SEEGMILLER: I would like to report one experience that we  have had 
with phenylbutazone, given in a dose of only 800 mg. for a single day, 
that has caused me to relegate this drug to second place in the manage- 
ment of gout. In this patient a thrombocytopenia developed which would 
have gone undetected if he had not been under study in the hospital. The 
drug was of course discontinued and the patient suffered no serious conse- 
quences from this as his platelet count returned to normal. I can visualize 
the possibility of more serious difficulties having been experienced if he 
had been taking the drug at home. 
I agree with Dr. Robinson that daily colchicine provides a valuable agent 
for preventing acute attacks. I don’t think any of us would recommend the 
continuous use of phenylbutazone or oxyphenbutazone for this purpose. 
DR. ROBINSON: I would like to underscore what Dr. Seegmiller has said: 
there is no question as to the usefulness of phenylbutazone in the treatment 
of acute attacks; there is no question of its being better than colchicine in 
the management of the patient with a well advanced attack or the patient 
with a polycyclic attack in whom colchicine has an incomplete efiect. In  
such patients, phenylbutazone permits you to get the inflammatory element 
under control in a way that we couldn’t do when we had only colchicine. 
However, when I prescribe a maintenance agent or instruct the patient 
in the use of an agent to abort attacks of gout, I can prescribe colchicine 
with full confidence that if the patient gets into trouble with toxicity he 
will know it, and he will stop the drug. I cannot have such confidence in 
prescribing phenylbutazone and trying to instruct the patient in the safe 
use of this drug to prevent or abort attacks of gout. For this reason I reserve 
phenylbutazone for patients that I have right under my thumb, either in 
the hospital or in town. 
DR. C .  SMYTH: We have seen acute massive gastrointestinal hemorrhage 
after the first day of treatment of acute attack of gout which 1 attributed to 
Butazolidine. The potential hematopoietic toxicities of this drug are now well 
known, and although we personally haven’t had this experience in some 60 
acute attacks, I think that most of us would agree that these hazards are 
real and we should stress them in this discussion. 
DR. HALL: May I ask Dr. Robinson a few short questions? You had an 
11 per cent incidence of renal calculi, were these all in patients who had had 
renal calculi prior to taking uricosuric agents? And once you’ve had a pa- 
tient on long term uricosuric therapy and you feel that you have reduced 
the frequency of the acute attacks, do you still continue with maintenance 
colchicine? 
DR. ROBINSON: In this group of 64 patients, renal calculi occurred in five 
patients prior to use of uricosuric drugs, and in seven patients during adminis- 
tration of the drugs. These figures include a single patient with symptoms 
of urinary tract calculi both before and after initiation of uricosuric therapy. 
In answer to the second question, we have usually continued maintenance 
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colchicine, &cause frankly we do not know when to stop it. Several patients 
in whom acute gout was well controlled on a regimen of both maintenance 
colchicine and uricosuric drugs, on stopping colchicine experienced recur- 
rence of acute gouty attacks. One patient ( a  physician) was able to stop 
colchicine without difficulty after several years on successful combined 
therapy. 
DR. HALL: At the time of instituting uricosuric therapy, did you alkalinize 
the urine of the patients? 
DR. ROBINSON: Not routinely, but we do make a very real effort to maintain 
a large urinary volume. 
DR. GUTMAN: Dr. Robinson has raised a question that I think might bear 
discussion, the question when to begin uricosuric therapy. There is no 
uniformity of opinion on this point and there probably should not be be- 
cause this is a decision that I think has to be made by the individual physi- 
cian. I don’t know of any rules that apply to every case, and a great deal 
depends, it seems to me, upon the attitude of the physician, the patient, the 
patient’s family, and all the other pressures that physicians are under when 
they face the question of medication. 
I do, however, want to comment on what is I think quite widely considered 
to be one of the more important indications for uricosuric therapy at a 
relatively early stage, even before the first attack of gouty arthritis, in pa- 
tients who have hyperuricemia. That is the hope, and I think it’s a forlorn 
hope, of preventing renal damage. The reason I have doubts about this is 
that, first of all, I have never convinced myself that we have been able to 
prevent renal damage, nor have I been convinced in any of our cases that 
we have improved renal function by the use of uricosuric agents, although 
I daresay we can on occasion mobilize the tophi in the kidney as we can 
elsewhere. But when you consider all the connective tissue reaction to uric 
acid crystals, inflammatory cell invasion, and all the rest of the tissue damage 
that accompanies the deposition of uric acid crystals, it seems unlikely that 
even if we do mobilize the uric acid crystals in the kidney that we can, in so 
doing, restore a badly damaged kidney to normal function. 
I do in particular want to add some relevant theoretical considerations. 
In all likelihood the site of reabsorption of uric acid by the human kidney 
is the proximal convolution, and probably very far up in the proximal 
convolution. What we are hoping to accomplish with uricosuric agents is 
to diminish the quantity of uric acid that is passing through the proximal 
convolution and thereby avoid the deposition of uric acid. But you must 
realize that when you give even the most potent uricosuric agents, you 
diminish the rate of tubular reabsorption of uric acid to the extent of per- 
haps 20 per cent. If you calculate the increase of urinary uric acid excre- 
tion produced and relate it to the quantity of uric acid which is filtered at 
the glomerulus, you realize that even though the increase in urinary uric acid 
excretion is considerable in terms of what is normally excreted, in terms of 
the huge amount of uric acid filtered at the glomerulus and reabsorbed, this 
is a very small proportion indeed. 
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Moreover, and I think this is a more serious objection, the pathologists 
tell us that the site of renal damage due to uric acid stone formation is not 
in the proximal convolution, but in the medulla, or a t  the junction between 
the medulla and the cortex; in other words, at the site of the distal tubule 
or in the collecting duct. We have no reason to believe that reabsorption 
occurs in these places to any appreciable extent, so the real damage to the 
kidney is by formation of uric acid microcalculi, which probably form at a 
site different from that which is affected by the use of uricosuric agents. I 
would go even further and say that by increasing renal excretion of uric 
acid we are further endangering, or facilitating this process of precipitation of 
uric acid in the collecting ducts and distal tubules. It is there that the urine 
is chiefly concentrated, in this way increasing the concentration of uric acid 
in the tubular fluid, and it is there also that the urine is chiefly acidified, 
so the chief conditions for facilitation of uric acid precipitation are not in the 
proximal tubule, but in the distal tubule and in the collecting ducts. 
So, on the basis of empirical experience and on the basis also of theoretical 
considerations, I think it highly unlikely that the administration of uricosuric 
drugs diminishes the hazard of uric acid deposition in the kidney. There is 
every reason to believe that, if anything, it increases the hazard, and this 
of course is borne out by the fact that there is a small but definite percentage 
of iatrogenic uric acid stone formation related to the use of uricosuric agents. 
D R .  BARTELS: Gout is a unique disease in that you can predict whether 
you are going to be able to bring it under control or not by establishing 
the state of the patient’s kidney function. In this way it can be decided 
whether you can effectively treat the patients. If one classifies the gouty 
patients according to their treatability one comes up with some different 
figures than have been shown here by Dr. Robinson. 
If a patient has no renal disease one can be relatively sure that the uri- 
cosuric drugs will be effective. Should one find some degree of renal in- 
sufficiency, as evidenced by the presence of albuminuria or a change in PSP 
or elevation in the BUN, one should not at that juncture say that these pa- 
tients are not treatable. In that case a determination of urinary excretion 
under the influence of various drugs should be undertaken. We have done 
this in a sizable group of patients whom we thought were untreatable and 
have found that sometimes they did respond by increasing the urinary ex- 
cretion of uric acid. Some 17 per cent of our patients have renal damage as 
a result of which there is no possibility of producing any uricosuric effects. 
DR. SEEGMILLER: My experience has been that even with the degree of 
renal impairment that gives a PSP excretion as low as 25 per cent in two 
hours one can obtain an increase in uric acid excretion with the uricosuric 
drugs, particularly sulfinpyrazone; probenecid giving some additive effect 
when given simultaneously. I think the resulting uricosuria still can produce 
a significant change in the course of the disease. With the advent of allo- 
purinol the prospect of effective control of such a patient has been greatly 
enhanced. 
While we’re on this subject no one has mentioned the study of Reed 
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which is very pertinent, In 11 of 20 patients with renal dysfunction and gout, 
she was able to achieve a mean increase in creatinine clearance of from 55 
to 75 ml./min. by treatment with a uricosuric drug (zoxazolamine), a high 
fluid intake and alkali. It is not clear from her study as to just which thera- 
peutic ingredient was responsible for these results. Do you have any opinion 
or data on this point from your clinical studies, Dr. Bartels? 
DR. BARTELS: As I mentioned, by doing these acute experiments and 
seeing how much uric acid is excreted, one has some idea as to whether 
they are controllable or not on uricosuric drugs. 
DR. SMYTH: This would amount to 17 per cent of your cases? 
DR. BARTELS: That’s right. 17 per cent of our patients have such a degree 
DR. SEEGMILLER: At what level of BUN do you make this decision? 
DR. BARTELS: I do not think anyone had a BUN over 40 mg. per cent. I 
believe there should be studies in this area. No patient should be eliminated 
from this therapy unless this test is done. 
DR. DECKER: I’d like to direct a question to Dr. Gutman. It is evident that 
the use of uricosuric drugs puts more uric acid into the tubule and delivers 
it to the site where it may do damage. Under these circumstances, we should 
reconsider the whole problem of prophylactic uricosuria in the essentially 
healthy individual who has had no gouty attacks, has had no tophi, but 
has an elevated serum uric acid. I wonder if this is ever justified. Is there 
then an indication for giving uricosuric agents solely on the basis of the 
level of the serum uric acid? Dr. Hall has given us good reason to believe 
that a substantial proportion of these people are going to their graves without 
ever knowing about their serum uric acid. Would you care to comment 
on this question? 
DR. GUTMAN: I’ve always been very conservative in the use of uricosuric 
agents. We have usually refrained from administration of uricosuric agents 
until we see the first indication of tophaceous deposit. Now, maybe that’s 
too conservative. 
But the thinking behind this is this: you must remember that hyper- 
uricemia begins in males at the age of puberty, so that by the time you 
see your patients at the age of 35, 40 or 45, they’ve already had hyperuricemia 
of essentially the same degree for 20 or 30 years when they first consult you. 
The administration of uricosuric drugs is therefore no acute emergency. 
We know also from the results of epidemiological studies that there are 
many more patients who have hyperuricemia than ever develop even a 
single attack of acute gouty arthritis. It is likely that most patients who have 
the gouty trait never develop any clinically overt manifestations of the dis- 
ease. Somewhat less than half of all patients who do develop overt gout, 
and these again are the minority of patients with the gouty trait, ever develop 
any tophi at all, and of this proportion only a small fraction ever form 
tophi of such extent as to represent any appreciable cosmetic or physical 
disability. So, the indications for uricosuric therapy in the way of prevention 
of tophi apply to only a diminishingly small proportion of the gouty popula- 
tion. 
The average interval between the first attack and the first tophus is 
of renal damage that there is no uricosuric response at all. 
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about ten years or so (11.2 Dr. Tiliyngaarden says). You are therefore 
faced with the prospect of giving a drug for prophylactic reasons over a 
very long period indeed to a patient who has less than a 50-50 chance of 
ever developing appreciable tophaceous deposits. Fortunately, probenecid and 
sulfinpyrazone are not very toxic, but they are not wholly innocuous and are 
rather expensive. It seems to me that the odds, under these circumstances, 
rather favor the point of view of withholding uricosuric agents. The really 
important question is: can you prevent renal damage? As I said before, I 
think the answer to that question is probably “No.” Therefore, everything 
considered, I’ve maintained a rather ultraconservative point of. view in re- 
gard to the administration of uricosuric agents. That’s one side of the pic- 
ture. NOW, the other side is, when patients come in to see me and I dis- 
cover, even in the asymptomatic patient, a serum uric acid level of 10 or 
12 or more milligrams per cent, I get a little nervous about this, and for the 
benefit of the physician as much as of the patient, we give uricosuric agents. 
DR. KRAKOFF: I just want to comment that Dr. Gutman’s nervousness in 
the face of a serum uric acid of 10 or 12 mg. per cent was probably minor 
compared to the frenzy of the house officer who sees a leukemic patient 
with a serum uric acid of about 25 mg. per cent. The temptation of the 
house staff in these situations to give probenecid immediately is enormous. 
Whatever useful role I might have been able to play is largely in restrain- 
ing these patients from receiving probenecid. I am quite sure that I have 
seen patients who were tolerating a serum uric acid level of 20 to 25 mg. 
per cent with a good urine output, who have been pushed into uric acid 
nephropathy and renal failure by the injudicious administration of uricosuric 
drugs in this situation. 
DR. BAUM: Dr. Gutman, in your view of this, then, the deposition of uric 
acid in the kidney in the patient with a high serum uric acid is not due 
to the high blood level but to the large amount of uric acid that’s leaving 
the kidney. I thought it was the feeling among pathologists that the deposi- 
tion in the interstitium of the kidney in patients with gout was more related 
to the elevated blood level than to the amount being excreted. In this 
event, wouldn’t you think that uricosuric therapy would be the treatment 
of choice because as you clear tophi from the periphery you are clearing, 
in a sense, microtophi from the interstitium of the kidney? 
DR. SMYTH: Dr. Gutman, do you want to reverse your decision previously 
stated? 
DR. GUTMAN: No. It may sound strange, but I think that the develop- 
ment of tophi peripherally, in the joints, etc., is certainly related to the 
serum uric acid level whereas in the development of tophi in the kidney, I 
suspect, this is not the case. In other words, in the kidney we have a rather 
special situation in which the damage, I believe, is due more to the excre- 
tory process. The concentration of uric acid in the urine, the pH of the 
urine, and the volume of the urine, these are the factors I think are paramount 
in importance in determining the extent of renal damage. I think that what 
Dr. Robinson said in reference to maintenance of high urine volumes is the 
simplest and most effective way we have of preventing renal damage. 
DR. H. SMYTHE: Dr. Decker’s and Dr. Gutman’s argument can be attacked 
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on two points. The first one is this question about the excessive delivery of 
uric acid to the tubules on uricosuric therapy. This does occur in the first 
few weeks of treatment, but after treatment is established the mean uric 
acid output is the same as before treatment. Therefore, you have to pro- 
tect the patient during a relatively short period of initiation of therapy by 
initiating therapy slowly, by maintaining high fluid volumes, and by alkal- 
inization of the urine fairly carefully, with testing of the urine with nitrazine 
papers. I think this should be done and is logical treatment. 
But perhaps the more important objection to their line of argument is 
the assumption that the renal failure is due to tophaceous deposits in the 
kidney. These are very spectacular lesions but they are spotty and incon- 
stant. Dr. Sokoloff and other pathologists describe a more important lesion 
leading to renal failure, namely nephrosclerosis. The degenerative vascular 
complications associated with gout may be related to the same basic prob- 
lem that leads to the risk of coronary heart disease in gouty subjects. For 
this reason much of our concern about the development of future therapy 
should be directed toward a study of the degenerative vascular complica- 
tions of gout. 
DR. SEECWILLER: I’ve been interested in Dr. Gutman’s thoughts on the 
evolutionary value of conservation of uric acid by the renal tubule. It seems 
to me that it may have had a survival value only when a paucity of water- 
ing holes presented a greater chance of dehydration than we generally 
experience today. Nature has performed an experiment observed SO far in 
only one person that is pertinent in this regard. Kirk and Praetorius reported 
studies of a man who seemed to lack a tubular reabsorptive mechanism for 
uric acid. In this regard he was the human counterpart of the Dalmatian 
coach hound. He  should therefore be experiencing all of the hazards that 
Dr. Gutman has been describing. As I recall there was no history of kidney 
stones or renal damage in this patient. There are clinical experiences that 
suggest the importance of a high fluid intake in augmenting uric acid ex- 
cretion. I have a family in which there are three gouty overproducers of. 
comparable renal function who, without uricosuric drugs, and while con- 
suming a purine-free diet, excreted around 1,100 milligrams of uric acid per 
day-two to three times the normal. Presumably they all share the same 
basic metabolic defect of overproduction. Two of the brothers had ex- 
perienced kidney stones. The third one who had not had kidney stones had, 
on his own volition, followed the advice to drink fluids that had been given to 
his other brothers and was found to be excreting over 6 liters of urine per 
day. He had the lowest serum urate concentration of the three. Augmenta- 
tion of uric acid clearance at high urine flow rates has been documented in 
the studies of Rieselbach and associates. There are reports in the literature 
of uric acid renal calculi undergoing reabsorption with a high fluid and alkali 
treatment. We have seen one gout patient in whom this occurred. 
All of these considerations point to the importance of a high fluid intake 
in gout patients to aid in the excretion of uric acid. If the hazards described 
by Dr. Decker and Dr. Gutman are extremely grave we should expect to 
see some evidence of kidney damage as the result of uricosuric therapy. I 
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haven’t seen any cases in which I felt that uricosuric therapy had a deleter- 
ious effect on kidney function. 
DR. WYNGAARDEN: There was a case report in the Rhode Island Medical 
Journal some years ago describing a patient whose renal function was made 
markedly worse by uricosuric therapy; from the data there it did not seem 
that it was due to stone and crystal formation induced by advancing renal 
failure. 
Dr. Seegmiller’s comments remind me of a point which perhaps should 
have been made earlier in the conference when we were discussing genetic 
patterns, that is the consistency of type within a given family. He  mentioned 
three overproducers in one family. We have a family with two overproducers, 
brothers, in one family, and another family with two brothers and a son 
with gout, all of whom have very high uric acid levels and normal glycine 
incorporation. One of them has a normal PRPP turnover and they all have 
very low clearance of urate. 
DR. GUTMAN: Would you agree that the incidence of uric acid stone 
generally is higher in people getting uricosuric agents? 
DR. SEEGMILLER: It is my impression that much depends on the precau- 
tions that one can induce patients to take. We do insist on 3 liters of fluid 
intake a day and really emphasize it at each visit. If the patient is an over- 
producer of uric acid or has a history of stones, we add alkali. When we 
first started using sulfinpyrazone without strong emphasis on these precau- 
tions one of our patients did develop renal colic and passed a stone. Since 
that time we’ve had really very little difficulty with uric acid stones. A few 
of our patients have passed calcium stones at various times. 
I should like to mention another group of three patients that has been 
instructive. These are patients who have come to us because of uric acid 
stones before they had ever developed any joint symptoms. They had fre- 
quent hematuria and had had recurrent passage of stones and at times had 
daily sludge in the urine. They were all overproducers of uric acid. We man- 
aged them with a high fluid intake and a large amount of alkali (15 grams of 
sodium bicarbonate or trisodium citrate per day) and ever since starting 
this therapy they have had no difficulties at all with stones. 
DR. GUTMAN: I wish all treatment were conducted as well as yours but 
unfortunately it is not. So many patients are referred to us by other physi- 
cians for just this problem, the precipitation of uric acid stones, and we 
contribute to the percentage to some extent ourselves. 
If you increase the concentration of uric acid in the urine and maintain 
a low pH, you facilitate the precipitation of uric acid stone. Now, if you 
counteract this conscientiously by giving large fluid volumes, if the urine pH 
is very low and you give alkali, you can overcome the hazard. In carefully 
conducted practices this is usually successful, but not all patients are as care- 
fully followed and not all patients carefully follow instructions. In Israel, 
for example, where the temperature is very high, there is an incidence of 
70 per cent of stone among gouty patients as compared to something be- 
tween 10 and 20 per cent in this area. I suppose that the danger even in this 
country would be greater in hot weather after exercise. 
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DR. BARTELS: In reference to the comments made by Dr. Gutman, the 
question is, is the danger of stone formation based on the amount of uric 
acid which is delivered to the kidney, or the amount which goes through 
the kidney? Based on the assumption that it is related to the amount de- 
livered to the kidney, we have intentionally, in some 39 patients who are 
stone formers with high serum uric acid, treated these patients with uricosuric 
drugs, and in this group we have not seen an increase in the incidence of 
stones; actually the reverse. A fair number of these patients have been 
individuals who have had previous surgery for stone removal and even 
n ephrectomy . 
DR. OGRYZLO: I think the comments about the urine volume in regard to 
keeping the urates in solution are very pertinent. I was interested in Dr. 
Seegmiller’s description of his patient with changes resulting from alterations 
in urine volume alone. We took 20 normals and 20 gouty patients and put 
them on a study where they had one day of intake of 1,000 cc’s; compared 
that with one day of intake of 4,000 cc’s; no other change, one day of a com- 
plete fast, and one day of a uricosuric agent. 
The only things that altered the urinary excretion or changed the serum 
uric acid value were the fasting and uricosuric agent. There was no significant 
change in excretion a t  all on simply changing urine volume from 1,000 to 
4,000 cc’s a day. 
The other question in regard to stones is, their occurrence in patients 
who do not have gout. These are patients referred by the genitourinary 
service who don’t have gout or hyperuricemia and whose urinary output 
is only of the order of 400 to 500 mg. per day. Now how do you explain this? 
DR. GWTMAN: Such patients, according to Dr. Henneman, have a very 
acid urine pH. 
DR. DECKER: I would like to mention an observation we made which was 
of in‘terest to us. The tranquilizing drug, chlorprothixene or Daractan, in 
daily dose of 50 mg. was as uricosuric as sulfinpyrazone, 200 mg., or pro- 
benecid, 500 mg. This drug is similar to a phenothiazine but is not a pheno- 
thiazine and it is also basic, not an acid. It has been used as a tranquilizer for 
four years and has a good safety record. In a representative clearance study, 
using it at bedtime for three days, the serum urate changed in this subject 
from 7.5 mg. per cent to 5 mg. per cent and the uric acid clearance 
was doubled from 7 to 15 cc. per minute. 
DR. C. SMYTH: Dr. Howell, would you like to comment on your exper- 
iences with Griseofulvin? 
DR. D. HOWELL: I really have very few statements to make about this 
agent. We became interested in it as a result of the finding that this drug 
had two properties of some interest. One, it interrupts cell division in various 
tissue cultures, and in other systems interrupts cell division at the metaphase, 
but probably more important it interferes with granuloma formation in cotton 
pledgets planted in various animals. 
We initially reported a study with a dramatic effect in acute gouty arthri- 
tis in 20 patients, with a prompt and complete response in all but two. There 
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were practically no side effects. We have tried 12 more patients since our 
formal report of 1962. We have limited its use to a certain group, those who 
have active peptic ulcers with danger of bleeding, perforation or uncontrollable 
pain who also have acute gout and in whom it is unwise therefore to use 
colchicine orally. 
All but one of these patients have done well on a schedule of management, 
which included 10 to 12 capsules of the new 0.25 gram Griseofulvin given 
by mouth over a period of three days. Rapid defervescence of objective signs 
of acute inflammation occurred with these patients. This was the same 
good response that had been observed in our first series. However, the prob- 
lem of the expense of the drug and the large number of capsules required 
makes me hesitate to recommend this drug as the best way to manage such 
patients. In our experience, given intravenously, we have found it to be 
rapidly effective, it is inexpensive, and without side effects. I would say 
that one could choose between these two methods of approach to the pa- 
tient who does not tolerate or in whom it is unwise to use oral colchicine. 
DR. ZVAIFLER: Has porphyria been seen in human patients? I know it has 
been recently produced in animals with this agent. 
DR. D. HOWELL: I believe that at human dosage levels porphyria does 
not occur. 
DR. ELDER: I t  might be worth mentioning one other drug that we’ve 
been looking at. We haven’t enough experience yet to report this with a great 
deal of confidence but we’ve been using indomethacin in our rheumatoid pa- 
tients. The British have already published several reports on the use of 
indomethacin in acute gouty arthritis, and in the last month I’ve had the 
opportunity to treat four patients with attacks of acute gout with indomethacin. 
We start with an empiric dose of 150 mg., which has been our average total 
daily dose, but in acute gout we have given 150 mg. as a stat oral dose. 
Two of the patients we saw within 24 hours of the time of their acute at- 
tack and one had typical podagra, the other one had an attack involving the 
wrists; both hobbled into the clinic, one unable to walk, the other unwilling 
to allow anyone to examine his arm, and within about half an hour to 45 
minutes after taking 150 mg. of indomethacin by mouth both of them were 
essentially pain free. They still had some swelling and erythema, which disap- 
peared over the next 48 hours or so, requiring no further use of the drug. 
The other two patients had been having their attack for approximately 
three days in one case, in the other case about five days and had been re- 
sistant to Butazolidine, colchicine and also steroid. In neither of these two 
cases was indomethacin quite as effective although both of them obtained 
quite a dramatic response over a 24 hour period. 
DR. PLOTZ: We have been using indomethacin now for about three years 
and our experience and the collected experience of others comprises some 
500 cases of acute gouty arthritis. There is very little doubt, as was 
previously pointed out, that indomethacin is an effective anti-inflammatory 
drug in the management of acute gout as in other acute inflammations. 
The first effect is observable within about two hours and we have found 
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that we will occasionally get a rebound unless indomethacin is continued 
for a period of five to seven days, unlike colchicine. Unlike phenylbutazone, 
there is no uricosuria with indomethacin; there is no effect on the serum 
urate level. Also unlike phenylbutazone and colchicine, there is very little 
risk of any serious side reaction. About 15 per cent of patients develop either 
headache or dizziness but this is transitory and other than this there are, 
except in the presence of overt peptic ulcer, virtually no side reactions, at 
least in the management of acute gouty arthritis. We have also in a most 
preliminary way, found that indomethacin has no apparent effect on the 
action of probenecid. 
